We concluded that in the highly heterogenous setting of primary DLBCL, the presence of an IRF8 mutation associates with a TME signature characterized by depletion of a series of proinflammatory/anticancer cell types (of the innate and adaptive immune system) and a potential increase in the suppressive Tregs. The gene discussed is IRF8; the disease is diffuse large B-cell lymphoma.